EF Hutton Maintains Buy on CollPlant Biotechnologies, Maintains $14 Price Target
Portfolio Pulse from Benzinga Newsdesk
EF Hutton analyst Jason Kolbert has reiterated a Buy rating for CollPlant Biotechnologies (NASDAQ:CLGN) and maintained a price target of $14.
August 20, 2024 | 4:28 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
EF Hutton analyst Jason Kolbert has reiterated a Buy rating for CollPlant Biotechnologies and maintained a price target of $14, indicating confidence in the company's future performance.
The reaffirmation of a Buy rating and a $14 price target by EF Hutton suggests positive sentiment and confidence in CollPlant's future performance, likely leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100